Resolution of transfusion dependence by recombinant human erythropoietin (rHuEPO) in acquired pure red cell aplasia (PRCA) associated with myeloid metaplasia

Publisher Website
Google Scholar
Abstract
Summary A patient with acquired pure red cell aplasia and agnogenic myeloid metaplasia (AMM) was treated with rHuEPO. She became transfusion independent. Weekly injections of rHuEPO have maintained the response without side‐effects or disease progression. In addition, marrow fibrosis and splenomegaly have decreased. Therefore, rHuEPO may be effective therapy for some patients with acquired PRCA and/or AMM.